CAJ | 학술논문

目的观察DCF方案(多西他赛+顺铂+氟尿嘧啶)一线治疗进展期胃癌的临床疗效和不良反应.方法收集我院2007年7月至2011年2月经病理和影像学确诊的61例进展期胃癌患者的临床资料进行回顾性分析.DCF方案:多西他赛75 mg/m2静脉滴注,第1天；氟尿嘧啶750 mg/m2持续静脉滴注24h,用化疗泵持续静脉滴注120 h(第1～5天)；顺铂75 mg/m2第1天静脉滴注,所有患者至少用药3个周期.对近期客观疗效及不良反应进行评价.结果治疗有效率为34.4％(21/61),疾病控制率为82.0％(50/61),中位无疾病进展时间为6.2个月,中位总生存期为10.1个月.中性粒细胞减少发生率为86.9％(53/61),其中Ⅲ～Ⅳ级为72.1％ (44/61),恶心呕吐发生率为80.3％(49/61),Ⅲ～Ⅳ级占18.0％(11/61).结论 DCF方案一线治疗进展期胃癌疗效较好,但骨髓抑制毒副作用较明显,可以作为一般状态较好的进展期胃癌患者有效化疗方案的选择.
목적 관찰DCF방안(다서타새+순박+불뇨밀정)일선치료진전기위암적림상료효화불량반응.방법 수집아원2007년7월지2011년2월경병리화영상학학진적61례진전기위암환자적림상자료진행회고성분석.DCF방안:다서타새75 mg/m2정맥적주,제1천；불뇨밀정750 mg/m2지속정맥적주24h,용화료빙지속정맥적주120 h(제1～5천)；순박75 mg/m2제1천정맥적주,소유환자지소용약3개주기.대근기객관료효급불량반응진행평개.결과 치료유효솔위34.4％(21/61),질병공제솔위82.0％(50/61),중위무질병진전시간위6.2개월,중위총생존기위10.1개월.중성립세포감소발생솔위86.9％(53/61),기중Ⅲ～Ⅳ급위72.1％ (44/61),악심구토발생솔위80.3％(49/61),Ⅲ～Ⅳ급점18.0％(11/61).결론 DCF방안일선치료진전기위암료효교호,단골수억제독부작용교명현,가이작위일반상태교호적진전기위암환자유효화료방안적선택.
Objective To evaluate the efficacy and tolerability of paclitaxel combined with cisplatin and fluorouracil (DCF) regimen as first line therapy for advanced gastric cancer (AGC).Methods Data from sisty-one patients treated with docetaxel with a dose of 75 mg/m2 on Day 1,cisplatin with a dose of 75 mg/m2 on Day 1 and infusional 5-fluorouracil with a dose of 750 mg/( m2 · day) on Days 1 to 5 (DCF) regimen.All the cases received DCF for at least 3 cycles and efficacy can be evaluated as well.Results The response rate (RR) was 34.4％ and the disease control rate (DCR) was 82.0％.The median progression-free time(mPFS) and median overall survival time (OS) were 6.2 and 10.1 months respectively.72.1％ of cases developed treatment-related grade 3 or 4 granulocytopenia.Conclusion DCF regimen is effective but with high hematologic toxicity rate and it can be a promising therapy for AGC cases.